C4 Therapeutics (CCCC) Net Margin (2019 - 2026)
C4 Therapeutics (CCCC) recorded quarterly Net Margin of 408.47% in Q1 2026, down 120.95% quarter-over-quarter from 184.87% in Q4 2025, and down 4480.0% on a YoY basis from 9.33% in Q1 2025.
C4 Therapeutics (CCCC) Net Margin (2019 - 2026) Analysis & Trends
C4 Therapeutics' Net Margin history runs 8 years deep, the most recent figure standing at 408.47% for Q1 2026.
- In Q1 2026, Net Margin fell 4480.0% year-over-year to 408.47%; the TTM figure through Mar 2026 stood at 297.41% (down 3781.0% YoY), while the FY2025 annual figure was 292.08%, up 388.0% from the prior year.
- Net Margin was 408.47% for Q1 2026 at C4 Therapeutics, down from 184.87% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 147.56% in Q2 2024 to a low of 1348.42% in Q2 2023.
- Historically, Net Margin has averaged 560.14% across 5 years, with a median of 408.47% in 2026.
- The sharpest annual moves came in 2022 and 2024: Net Margin plunged 122492 bps in 2022, then surged 120086 bps in 2024.
- A 5-year view of Net Margin shows it stood at 1302.91% in 2022, then increased by 18 bps to 1065.84% in 2023, then jumped by 37 bps to 667.82% in 2024, then soared by 72 bps to 184.87% in 2025, then slumped by 121 bps to 408.47% in 2026.
- The last three Net Margin figures came in at 408.47% (Q1 2026), 184.87% (Q4 2025), and 286.43% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | C4 Therapeutics | 520.69 Mn | 285.02 Mn | - | -408.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -408.47% |
| Dec 31, 2025 | -184.87% |
| Sep 30, 2025 | -286.43% |
| Jun 30, 2025 | -402.60% |
| Mar 31, 2025 | -363.66% |
| Dec 31, 2024 | -667.82% |
| Sep 30, 2024 | -160.57% |
| Jun 30, 2024 | -147.56% |
| Mar 31, 2024 | -933.23% |
| Dec 31, 2023 | -1,065.84% |
| Sep 30, 2023 | -244.19% |
| Jun 30, 2023 | -1,348.42% |
| Mar 31, 2023 | -925.25% |
| Dec 31, 2022 | -1,302.91% |
| Sep 30, 2022 | -473.17% |
| Jun 30, 2022 | -194.29% |
| Mar 31, 2022 | -413.12% |
| Dec 31, 2021 | -77.99% |
| Sep 30, 2021 | -290.39% |
| Jun 30, 2021 | -230.86% |